When resting APCs encounter tumor-specific antigens, they mature and migrate to the lymph nodes, where they cross-present the tumor-specific antigens to naïve T cells in the germinal center.50 CD8+ T cells are therefore primed and activated against the specific tumor where the antigens come from. This evidence concerns the gene CD8A and neoplasm.